Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
about
Deficient mismatch repair: Read all about it (Review)A periodic table for cancerMolecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future PerspectiveRole of Deficient Mismatch Repair in the Personalized Management of Colorectal CancerColorectal Cancer Classification and Cell Heterogeneity: A Systems Oncology ApproachPredictive model for high-frequency microsatellite instability in colorectal cancer patients over 50 years of age.Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses.High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis.High Prevalence and Clinical Relevance of Genes Affected by Chromosomal Breaks in Colorectal Cancer.Improved Detection of Circulating Tumor Cells in Metastatic Colorectal Cancer by the Combination of the CellSearch® System and the AdnaTest®Reduced rate of copy number aberrations in mucinous colorectal carcinoma.MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal CancerHereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic targetEffects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers.Biomarker in Colorectal Cancer.BRAF V600E mutation in metastatic colorectal cancer: Methods of detection and correlation with clinical and pathologic features.Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients.Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.Clinical course and outcome of patients with high-level microsatellite instability cancers in a real-life setting: a retrospective analysis.Precision medicine in colorectal cancer: evolving genomic landscape and emerging consensus.Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers.New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.Mismatch repair deficiency testing in clinical practice.From tumour heterogeneity to advances in precision treatment of colorectal cancer.Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.Mismatch Repair Deficiency and Response to Immune Checkpoint BlockadeBRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment?Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.PI3K/Akt/mTOR Signaling and Plasma Membrane Proteins Are Implicated in Responsiveness to Adjuvant Dendritic Cell Vaccination for Metastatic Colorectal Cancer.Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy.Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors.Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma.Molecular Landscape and Treatment Options for Patients with Metastatic Colorectal Cancer.microRNA-193a-3p is specifically down-regulated and acts as a tumor suppressor in BRAF-mutated colorectal cancer.Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
P2860
Q26796491-DBC7F6A3-7DEA-43C5-BE1C-FE6626C8E599Q26858878-DBF9DD6C-EAD6-42E2-995D-E0C96E1BBC54Q28070038-B929A8F3-4B36-4765-BFBA-99F2E344FDB5Q28080176-30B5C607-27D5-402E-9F2F-3FFC74E134BDQ28647615-D1AEA59D-4317-451B-B072-BA370FC8C040Q33775336-B21ED2EE-0761-42F8-BBE8-6C800D4925C9Q33848817-3DF92BBF-7658-4F1F-B1ED-D1468D5165ECQ35677169-85C83BD1-982F-4F46-AB1A-98DCBBEBAE06Q35685684-989286DD-32E9-485A-883B-348089F2B288Q35777233-3E61C7B4-2EAE-4D9B-8805-888B14B26A88Q36018511-76158F8C-ECEA-47B5-9F52-A1F93C6BFBB9Q36413276-3F910924-0A37-481E-9AB8-F53E72C43C81Q36413436-EF64DE26-BE68-4516-B57C-A0EB15784E4AQ36558421-ABAE75EF-BF5E-451E-B5A4-B8733F7ACAC9Q36990060-EE86CADD-12D4-4C84-A8BE-A4A7D5D8828DQ37061363-9FA83C01-6CD7-4B70-BA92-CC6BC29B6B1DQ37114675-68F7611C-D985-465A-8C85-8AD1E734276AQ37216950-771F54C1-E4EB-4688-8997-FB6286EC4603Q37631539-2DC024BC-5C2F-4179-8D16-17027073908AQ37687487-DB6443A1-9C28-4617-9FA7-5C82F22421B4Q37741987-8E5A685F-184D-4746-88F0-BE3794772986Q38580566-1E6677C5-4382-48C3-81CB-347FEAED0DB5Q38683093-A2F86D2F-BB80-45AC-AFDD-D536B9ED7B4DQ38727912-8A5032EA-029F-4691-8FFC-1985E50168E3Q38741029-EE84E242-BEFA-48F2-83A3-A0B0A109F665Q38786707-51BE5261-5BB4-4D7F-8251-838688B46FB6Q38787278-CDBC3701-F206-4841-B1C0-7BFE641C21CAQ38868401-63633A7C-6752-49B3-AD60-91C60E8CBBECQ38895750-FEE5D820-FF80-44AE-9463-212BFE968008Q38953687-9941BF07-8472-4F7D-9CB4-2A3F03A24E5BQ39038545-7B48E747-B465-481B-9E6E-8465AC5AF41AQ39584017-47C3F8FE-19C0-4238-9A43-641D14FB12C9Q40040773-91C06057-4614-45FA-B7CF-69E396D89B42Q41111994-3D61D53B-592E-454A-AC2B-04F5D0A3254CQ41352188-2364199D-1A81-47A4-AD75-EC6FC32D4414Q41935304-3B4FD89A-8D5A-4E4C-9F66-DE7BFCCADEB7Q43138932-B595691E-8B62-4ED7-89DE-3DEC27A8448FQ45989066-E6FE62F9-8E83-45FD-BBAD-D597B46AE4B4Q47128749-AB8F9A26-0DA1-4824-90BE-BD6C3E1CF3A3Q47634752-96D50795-9C01-4D5F-A368-ACF0FC80BB06
P2860
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@ast
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@en
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@en-gb
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@nl
type
label
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@ast
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@en
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@en-gb
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@nl
prefLabel
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@ast
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@en
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@en-gb
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@nl
P2093
P2860
P50
P1154
2-s2.0-84909606012
P1476
Mismatch repair status and BRA ...... IRO2, COIN, and FOCUS studies.
@en
P2093
Anton F J de Haan
Christopher G Smith
Cornelis J A Punt
Danielle A M Heideman
David Fisher
Gerrit A Meijer
Iris D Nagtegaal
Jeremy P Cheadle
Matthew T Seymour
Miriam Koopman
P2860
P304
P356
10.1158/1078-0432.CCR-14-0332
P407
P5530
P577
2014-08-19T00:00:00Z
P6179
1039456488